We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is DexCom (DXCM - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DexCom is a member of our Medical group, which includes 908 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. DXCM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 27.40% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that DXCM has returned about 5.81% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -0.44% on a year-to-date basis. This means that DexCom is performing better than its sector in terms of year-to-date returns.
To break things down more, DXCM belongs to the Medical - Instruments industry, a group that includes 96 individual companies and currently sits at #103 in the Zacks Industry Rank. Stocks in this group have gained about 0.37% so far this year, so DXCM is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to DXCM as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is DexCom (DXCM - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DexCom is a member of our Medical group, which includes 908 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. DXCM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 27.40% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that DXCM has returned about 5.81% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -0.44% on a year-to-date basis. This means that DexCom is performing better than its sector in terms of year-to-date returns.
To break things down more, DXCM belongs to the Medical - Instruments industry, a group that includes 96 individual companies and currently sits at #103 in the Zacks Industry Rank. Stocks in this group have gained about 0.37% so far this year, so DXCM is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to DXCM as it looks to continue its solid performance.